Apogee Therapeutics CEO sells $1.64M stock, insider move

Apogee Therapeutics CEO Michael Henderson sold $1.64 million of company stock on May 15, 2026, Investing.com reported on 16 May 2026. The transaction was disclosed the following day. The sale size — $1,640,000 — is a material, single-day liquidity event by a named executive. This article summarises the timing, filing mechanics, potential market implications, and where to find the official documents.

Why did Michael Henderson sell $1.64M of Apogee stock?

The company filing shows the sale amount of $1,640,000 executed on May 15, 2026. Insider sales are routinely driven by personal liquidity needs, tax planning or scheduled trading plans; the filing does not assign a corporate governance reason. The CEO's position and the $1.64M magnitude make the move notable relative to routine small disposals by lower-level officers.

Direct inference about company fundamentals is not warranted from a single transaction. Limitation: an insider sale does not prove deteriorating fundamentals; executives often sell according to pre-set plans or to fund non-company obligations.

How was the sale executed and what filing records it?

The sale was reported via the standard insider disclosure process; insiders must use Form 4 for open-market transactions. Form 4 must be filed with the SEC within two business days of the trade date, which aligns with the May 15 trade and the May 16 report date. The disclosure will list the exact number of shares and price per share; the $1.64M value in the headline is the aggregate proceeds disclosed.

You can view the official Form 4 or company reports through public registries and on company filings pages. For consolidated tracking of similar moves visit our insider transactions hub at https://fazen.markets/en.

What does a $1.64M insider sale mean for Apogee’s stock and float?

A $1.64M sale increases immediate free-float liquidity by that amount, though the impact on the share count depends on the number of shares sold and outstanding shares. Without the exact share count from the Form 4, the post-sale ownership percentage cannot be calculated precisely. Investors often compare the sale size to the company’s market capitalization and average daily volume; the $1.64M figure is the baseline for those calculations.

Market reaction to single insider sales is typically muted unless the sale significantly alters an insider's ownership stake or coincides with adverse corporate news. Price moves, if any, will be visible in intraday and next-day trading volume and should be checked against the official filing timeline.

How should investors verify and contextualise this insider sale?

Start with the official Form 4 for the precise share count and price per share. The filing will state whether the sale was part of a Rule 10b5-1 trading plan or executed as an open-market transaction; a 10b5-1 plan often indicates pre-arranged timing. Rule-based sales can clarify whether the trade was pre-planned — that detail is key for interpreting intent.

For broader context, compare the sale to the CEO’s ownership stake and the company’s float. Our coverage at https://fazen.markets/en includes analyst commentaries and a historical database of insider moves for cross-reference.

Q: Where will I find the exact number of shares sold and the per-share price?

The exact share count and price per share are listed on the SEC Form 4 filed by the insider. Form 4 is due within two business days of the transaction date; check the filing dated May 16, 2026 for the May 15 trade. Public registries and the company’s investor relations page also host the filing.

Q: Does this sale change Michael Henderson’s ownership percentage in Apogee?

You need two numbers to compute the change: the number of shares Henderson sold (from the Form 4) and the company’s total outstanding shares. Outstanding shares are disclosed in the latest 10-Q or 10-K. Without those figures, the exact percentage change cannot be determined from the $1.64M aggregate value alone.

Bottom Line

The $1.64M sale is a material insider liquidity event for Apogee Therapeutics.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.